A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

Abroad (travel likely)RecruitingPHASE2

Conditions

Heart Failure With Preserved Ejection Fraction

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Mayo Clinic in Rochester, Rochester, Minnesota, United States
Contact: Study coordinator (Amyloid Research Team) · (507) 266-4426
Contact: Principal Investigator (Omar Abou Ezzeddine, MD, MS)

Study leads

Omar Abou Ezzeddine, M.D, M.S
Principal Investigator
Mayo Clinic
Gregorio Tersalvi, M.D
Principal Investigator
Mayo Clinic

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

Heart Failure

Abroad (travel likely)RecruitingPHASE2

Beverly Hills, United States · Lake Forest, United States

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Heart Failure With Preserved Ejection Fraction

Abroad (travel likely)RecruitingPHASE2

Philadelphia, United States

Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction

Abroad (travel likely)Recruiting

Winston-Salem, United States

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

Heart Failure · Acute Heart Failure

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Fairhope, United States